Fresh Funding Pushes Inflazome Into Clinic With Inflammation Inhibitors
With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.
You may also be interested in...
GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. CEO Neil Weir outlines Sitryx's raison d'etre.
European life science companies can expect to get access to almost €290m from Forbion as the EU-based venture capitalist closes its fourth fund at an oversubscribed €360m.
CSO and acting CEO of UK-Based biotech outlines to Scrip plans to develop next generation NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation.